Studienlage · Detail
Gemischt
GRADE
Moderat
143 Zitate
Stichproben = 1.348 Pat.
DauerDiagnosezeitraum Januar 1999…
KontrolleAltersgematchte bevölkerungsbasierte…
EndpunktTGCT-Inzidenz
Verblindungn.a.
DesignFall-Kontroll-Studie (populationsbasiert)
Applikationinhalativ
Kernaussage
Aktueller Cannabis-Konsum ist mit einem erhöhten Risiko für Nichtseminom-TGCT assoziiert, wobei früher Konsumbeginn und hohe Konsumhäufigkeit das Risiko weiter steigern.
Zusammenfassung
Populationsbasierte Fall-Kontroll-Studie (n=369 Hodenkeimzelltumor-Fälle, n=979 altersgematchte Kontrollen); aktueller Cannabis-Konsum war mit erhöhtem TGCT-Risiko assoziiert (OR=1,7; 95%-KI 1,1–2,5); bei Nicht-Seminom/gemischter Histologie OR=2,3 (95%-KI 1,3–4,0); täglicher/wöchentlicher Konsum OR=3,0; Erstkonsum <18 Jahren OR=2,8.
P
PopulationMänner im Alter 18–44 Jahre mit histologisch gesichertem Hodenkeimzelltumor (TGCT), n=369 Fälle; 979 altersgematchte Kontrollen aus Washington State, USA
I
InterventionCannabis-Konsum (aktuell, lebenslang, Beginnalter, Häufigkeit) – per Selbstauskunft erhoben
C
KontrolleAltersgematchte bevölkerungsbasierte Kontrollen ohne TGCT-Diagnose (n=979)
O
OutcomeAktueller Cannabis-Konsum assoziiert mit erhöhtem TGCT-Risiko (OR 1,7; 95%-KI 1,1–2,5); stärkste Assoziation bei Nichtseminomen/gemischter Histologie (OR 2,3; 95%-KI 1,3–4,0); Risikomodifikation durch Beginnalter <18 Jahre (OR 2,8) und täglichen/wöchentlichen Konsum (OR 3,0)
Vertrauen in die Evidenz
Moderat
Dritte von vier GRADE-Stufen, die Effektschätzung ist wahrscheinlich verlässlich.
Qualitätsprofil
Größe
★★★★★
Verblindung
—
Effektstärke
Gemischt
Zitate / Jahr
★★★★★
Autoren
Teilen
Abstract
<h4>Background</h4>The incidence of testicular germ cell tumors (TGCTs) has been increasing the past 4 to 6 decades; however, exposures that account for this rise have not been identified. Cannabis use also grew during the same period, and it has been established that chronic Cannabis use produces adverse effects on the human endocrine and reproductive systems. In this study, the authors tested the hypothesis that Cannabis use is a risk factor for TGCT.<h4>Methods</h4>A population-based, case-control study of 369 men ages 18 to 44 years who were diagnosed with TGCT from January 1999 through January 2006 was conducted in King, Pierce and Snohomish Counties in Washington State. The responses of these men to questions on their lifetime Cannabis use were compared with the responses of 979 age-matched controls who resided in the same 3 counties during the case diagnosis period.<h4>Results</h4>Men with a TGCT were more likely to be current Cannabis smokers at the reference date compared with controls (odds ratio [OR], 1.7; 95% confidence interval [95% CI], 1.1-2.5). In analyses according to histologic type, most of the association between current Cannabis use and TGCT was observed in men who had nonseminomas/mixed histology tumors (current use: OR, 2.3; 95% CI, 1.3-4.0). Age at first use among current users (age<18 years [OR, 2.8] vs age>or=18 years [OR, 1.3]) and frequency of use (daily or weekly [OR, 3.0] vs less than once per week [OR, 1.8]) appeared to modify the risk.<h4>Conclusions</h4>An association was observed between Cannabis use and the occurrence of nonseminoma TGCTs. Additional studies of TGCTs will be needed to test this hypothesis, including molecular analyses of cannabinoid receptors and endocannabinoid signaling, which may provide clues regarding the biologic mechanisms of TGCTs.
„Was dem Handeln im Weg steht, wird zum Weg.“